<DOC>
	<DOCNO>NCT00793312</DOCNO>
	<brief_summary>The primary objective document acute mid-term safety overall clinical performance Endeavor ( TM ) Zotarolimus Eluting Coronary stent system `` real world '' Chinese patient population require stent implantation . To assess event rate patient subgroup specific clinical indication and/or vessel lesion characteristic .</brief_summary>
	<brief_title>China Endeavor Registry : A Registry With The Endeavor Zotarolimus Eluting Coronary Stent China</brief_title>
	<detailed_description>The safety efficacy Endeavor ( TM ) Zotarolimus Eluting Coronary Stent System assess series study , e.g . ENDEAVOR I ENDEAVOR II . The stent compose cobalt alloy coat proprietary drug compound zotarolimus design reduce restenosis . This registry Endeavor ( TM ) Zotarolimus Eluting Coronary Stent System initiate 1 ) expand clinical knowledge base include 'real world'patients China 2 ) assess event rate Chinese patient know high risk major adverse cardiac event , example patient diabetes mellitus , small vessel long lesion . In total plan enroll 2200 patient 37 site . Follow-up one year main patient cohort collect acute mid-term follow-up data , extend two year certain patient subgroup .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>Patient &gt; 18 year age ( minimum age require local regulation ) . The patient consent participate signing `` Patient Informed Consent Form '' and/or authorize collection release medical information sign `` Patient Data Release Consent Form '' . Patient suitable implantation one Endeavor™ Zotaroliums Eluting Coronary Stent System one native artery target lesion . Patient indication , lesion length vessel diameter target lesion ( ) accord Indications Use ' mention 'Instructions Use ' come every Endeavor™ Zotarolimus Eluting Coronary Stent System . The patient willing able cooperate registry procedure require follow Women know pregnancy lactate . Patients hypersensitivity allergy aspirin , heparin , clopidogrel , ticlopidine , drug zotaroliums , rapamycin , tacrolimus , sirolimus similar drug , analogue derivative , cobalt , chromium , nickel , molybdenum contrast medium . Patients antiplatelet and/or anticoagulation therapy contraindicate . Patients judged lesion prevents complete inflation angioplasty balloon . Current medical condition life expectancy le 12 month . The subject participate another device drug study . Subject must complete followup phase previous study least 30 day prior enrollment trial . The subject may enrol Registry . Patients medical condition preclude followup define protocol otherwise limit participation registry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>